Introgen Appoints Thomas Finnegan as Vice President of Finance and Corporate Development

Apr 02, 2001, 01:00 ET from Introgen Therapeutics, Inc.

    AUSTIN, Texas, April 2 /PRNewswire/ -- Introgen Therapeutics, Inc.
 (Nasdaq:   INGN) announced today that G. Thomas Finnegan III has joined the
 company as vice president of finance and corporate development.
     "Tom is a welcome addition to our management team.  As a new public
 company, Introgen must now increase its visibility with opinion leaders in the
 financial markets," said David G. Nance, president and CEO of Introgen.
 "Tom's primary responsibility will be to increase shareholder value by raising
 the market's awareness of Introgen.  I look forward to working with Tom to
 develop strategies to maximize the value of Introgen's assets and
 opportunities.  Tom's experience with both the buy-side and sell-side
 communities provides the experience and relationships to help Introgen achieve
 its corporate development goals."
     "Job number one will be to increase the value of Introgen's shares," said
 Mr. Finnegan.  "I believe there may be an opportunity to increase the value
 potential of a number of assets at Introgen such as the intellectual property
 portfolio, manufacturing capabilities, and a rich technology pipeline.  I am
 excited to help the company tell its story about its near term product
 candidate, INGN 201, and to help Introgen gain the recognition it deserves."
     "We expect that Tom's activities will strengthen our strategic financial
 planning," said James W. Albrecht, Jr., chief financial officer of Introgen.
 "His efforts will compliment our control and finance operations."
     Since 1999, Mr. Finnegan has been associated with the Health Care
 Investment Banking division of SG Cowen where he was involved in corporate
 finance transactions in the equity, debt and private markets for the
 biotechnology, pharmaceutical, and e-health industries.  Prior to that Mr.
 Finnegan was an investment-banking associate for Merrill Lynch & Co. where he
 was involved in the organization and execution of various M&A transactions and
 equity offerings.  He previously worked as an equity analyst for both
 Forstmann Partners LP and Porpoise Investors.
     Mr. Finnegan also served as a board member for a publicly traded
 pharmaceutical company until 2000, when the company was acquired.  Mr.
 Finnegan earned an MBA degree from the Goizueta School of Business at Emory
 University and received a Bachelors degree from the University of South
 Carolina in 1990.  Mr. Finnegan will reside in Austin, Texas.
 
     Introgen is a leader in the development and production of gene-based drugs
 for the treatment of cancer and other diseases.  Introgen's product candidates
 engage precise molecular targets to produce a highly specific therapeutic
 effect.  Introgen specializes in combining appropriate gene delivery systems
 and therapeutic genes to make its gene-based drugs.  Introgen's lead product
 candidate, INGN 201, is currently in Phase III clinical trials for the
 treatment of head and neck cancer.  INGN 201 has been used in numerous
 clinical trials worldwide either alone or in combination with conventional
 treatments such as chemotherapy and radiotherapy.  Introgen is also conducting
 a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for
 INGN 201 in additional cancer indications including prostate, ovarian,
 bladder, brain, and breast cancer.  New applications using the human immune
 system with INGN 201 are being explored.  Introgen's second product candidate,
 INGN 241 (Adenoviral-mda7), for the treatment of solid tumors, is in Phase I
 clinical development.
 
     Certain statements in this press release that are not strictly historical
 may be "forward-looking" statements, which involve risks and uncertainties.
 Such forward-looking statements include, but are not limited to, those
 relating to safety and efficacy of drug product candidates.  There can be no
 assurance that Introgen will be able to commercially develop gene-based drugs,
 that necessary regulatory approvals will be obtained or that any clinical
 trials or studies undertaken will be successful or that the proposed
 treatments will prove to be safe and/or effective.  The actual results may
 differ from those described in this press release due to risks and
 uncertainties that exist in Introgen's operations and business environment,
 including, but without limitation, Introgen's stage of product development and
 the limited experience in the development of gene-based drugs in general, its
 dependence upon proprietary technology and current competition, history of
 operating losses and accumulated deficits, Introgen's reliance on
 collaborative relationships, and uncertainties related to clinical trials,
 safety, efficacy, the ability to obtain the appropriate regulatory approvals,
 patent protection and market acceptance, as well as other risks detailed from
 time to time in Introgen's filings with the Securities and Exchange
 Commission, including its prospectus dated October 12, 2000, filed with the
 Securities and Exchange Commission and the 10-Q filed with the Securities and
 Exchange Commission on February 14, 2001.  Introgen undertakes no obligation
 to publicly release the results of any revisions to any forward-looking
 statements that reflect events or circumstances arising from the date hereof.
 
 

SOURCE Introgen Therapeutics, Inc.
    AUSTIN, Texas, April 2 /PRNewswire/ -- Introgen Therapeutics, Inc.
 (Nasdaq:   INGN) announced today that G. Thomas Finnegan III has joined the
 company as vice president of finance and corporate development.
     "Tom is a welcome addition to our management team.  As a new public
 company, Introgen must now increase its visibility with opinion leaders in the
 financial markets," said David G. Nance, president and CEO of Introgen.
 "Tom's primary responsibility will be to increase shareholder value by raising
 the market's awareness of Introgen.  I look forward to working with Tom to
 develop strategies to maximize the value of Introgen's assets and
 opportunities.  Tom's experience with both the buy-side and sell-side
 communities provides the experience and relationships to help Introgen achieve
 its corporate development goals."
     "Job number one will be to increase the value of Introgen's shares," said
 Mr. Finnegan.  "I believe there may be an opportunity to increase the value
 potential of a number of assets at Introgen such as the intellectual property
 portfolio, manufacturing capabilities, and a rich technology pipeline.  I am
 excited to help the company tell its story about its near term product
 candidate, INGN 201, and to help Introgen gain the recognition it deserves."
     "We expect that Tom's activities will strengthen our strategic financial
 planning," said James W. Albrecht, Jr., chief financial officer of Introgen.
 "His efforts will compliment our control and finance operations."
     Since 1999, Mr. Finnegan has been associated with the Health Care
 Investment Banking division of SG Cowen where he was involved in corporate
 finance transactions in the equity, debt and private markets for the
 biotechnology, pharmaceutical, and e-health industries.  Prior to that Mr.
 Finnegan was an investment-banking associate for Merrill Lynch & Co. where he
 was involved in the organization and execution of various M&A transactions and
 equity offerings.  He previously worked as an equity analyst for both
 Forstmann Partners LP and Porpoise Investors.
     Mr. Finnegan also served as a board member for a publicly traded
 pharmaceutical company until 2000, when the company was acquired.  Mr.
 Finnegan earned an MBA degree from the Goizueta School of Business at Emory
 University and received a Bachelors degree from the University of South
 Carolina in 1990.  Mr. Finnegan will reside in Austin, Texas.
 
     Introgen is a leader in the development and production of gene-based drugs
 for the treatment of cancer and other diseases.  Introgen's product candidates
 engage precise molecular targets to produce a highly specific therapeutic
 effect.  Introgen specializes in combining appropriate gene delivery systems
 and therapeutic genes to make its gene-based drugs.  Introgen's lead product
 candidate, INGN 201, is currently in Phase III clinical trials for the
 treatment of head and neck cancer.  INGN 201 has been used in numerous
 clinical trials worldwide either alone or in combination with conventional
 treatments such as chemotherapy and radiotherapy.  Introgen is also conducting
 a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for
 INGN 201 in additional cancer indications including prostate, ovarian,
 bladder, brain, and breast cancer.  New applications using the human immune
 system with INGN 201 are being explored.  Introgen's second product candidate,
 INGN 241 (Adenoviral-mda7), for the treatment of solid tumors, is in Phase I
 clinical development.
 
     Certain statements in this press release that are not strictly historical
 may be "forward-looking" statements, which involve risks and uncertainties.
 Such forward-looking statements include, but are not limited to, those
 relating to safety and efficacy of drug product candidates.  There can be no
 assurance that Introgen will be able to commercially develop gene-based drugs,
 that necessary regulatory approvals will be obtained or that any clinical
 trials or studies undertaken will be successful or that the proposed
 treatments will prove to be safe and/or effective.  The actual results may
 differ from those described in this press release due to risks and
 uncertainties that exist in Introgen's operations and business environment,
 including, but without limitation, Introgen's stage of product development and
 the limited experience in the development of gene-based drugs in general, its
 dependence upon proprietary technology and current competition, history of
 operating losses and accumulated deficits, Introgen's reliance on
 collaborative relationships, and uncertainties related to clinical trials,
 safety, efficacy, the ability to obtain the appropriate regulatory approvals,
 patent protection and market acceptance, as well as other risks detailed from
 time to time in Introgen's filings with the Securities and Exchange
 Commission, including its prospectus dated October 12, 2000, filed with the
 Securities and Exchange Commission and the 10-Q filed with the Securities and
 Exchange Commission on February 14, 2001.  Introgen undertakes no obligation
 to publicly release the results of any revisions to any forward-looking
 statements that reflect events or circumstances arising from the date hereof.
 
 SOURCE  Introgen Therapeutics, Inc.